Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Simon Yoo

MOHS-Micrographic Surgery Chicago, IL Medical Doctor

NPI 1760466411 CMS profile 261095

259 E Erie St Ste 2020, Chicago, IL 60611

Open in the dashboard

General payments

$10,341

12 records reported · program years 2019–2024

Research payments

$1,350

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Simon Yoo of Chicago, IL is reported in the CMS Open Payments database as having received $10,341 across 12 general payments and $1,350 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $49 1
2023 General $23 1
2022 Research $1,350 1
2021 General $23 1
2020 General $5,025 2
2019 General $5,223 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Simon Yoo
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Simon Yoo were reported at $0. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Simon Yoo MOHS-Micrographic Surgery median Middle half National median
2019 $5,223 $316 $106–$785 $163
2020 $5,025 $162 $68–$412 $114
2021 $23 $243 $87–$654 $132
2022 $0 $300 $102–$887 $149
2023 $23 $364 $125–$1,010 $160
2024 $49 $445 $142–$1,108 $164
2025 $0 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Genzyme Corporation $5,223 7 payments
  2. Regeneron Healthcare Solutions, Inc. $5,000 1 payment
  3. Smith+Nephew, Inc. $49 1 payment
  4. Acera Surgical, Inc. $47 2 payments
  5. Sun Pharmaceutical Industries Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $10,049 2 payments
  2. Food and Beverage $273 8 payments
  3. Travel and Lodging $19 2 payments
Products named General payments · program years 2019–2024
  1. LIBTAYO Oncology $5,223 7 payments
  2. LIBTAYO Oncology $5,000 1 payment
  3. GRAFIX PL $49 1 payment
  4. Restrata Wound Matrix Wound Care $25 1 payment
  5. ILUMYA $23 1 payment
  6. Restrata Wound Matrix Wound Care $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. F. Hoffmann-La Roche AG $1,350 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

1,932

Median for Dermatology: 534

Drug cost

$15,509

Median for Dermatology: $67,151

Branded share of claims

10.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gentamicin Sulfate Generic 222 $6,188
Cephalexin Generic 1,027 $3,806
Mupirocin Generic 251 $1,638
Acitretin Generic 15 $1,558
Clindamycin Hcl Generic 144 $958
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 201 $726
Minocycline Hcl Generic 29 $351
Doxycycline Hyclate Generic 26 $176
Triamcinolone Acetonide Generic 17 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 123 billing codes

Paid by Medicare

$1,427,633

Of which drugs: $2,666

Medicare patients

1,228

Average age 76

Services billed

5,133

546 women, 682 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 42%
Ischemic heart disease 29%
Cancer 22%
Chronic kidney disease 21%
Diabetes 19%
Atrial fibrillation 19%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 108 288 $214

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record